Japan's ispace blames 'hard landing' on moon on Laser Range Finder
June 24 (UPI) -- Japanese company ispace said Tuesday that a "hard landing" during its attempted lunar landing in early June was due to an anomaly in the Laser Range Finder.
In the analysis of the "SMBC X HAKUTO-R VENTURE MOON" mission 2 ispace said the hard landing was due to an "anomaly in the laser rangefinder hardware," and the telemetry data also revealed no issues with the lander's software or propulsion system.
The LRF unit did not provide altitude measurement until it was less than half a mile off the ground. However, it was initially designed to provide altitude data when the spacecraft was at at least about 2 miles above the surface.
Laser light reflected back to the lander, lower power of the laser, reduced performance at higher velocities or effects from the space environment, such as a vacuum or radiation are several factors that could have played a role in the performance of the LRF.
"On June 6, despite the united efforts and dedication of the ispace team, our second attempt at a lunar landing was unsuccessful, resulting in deep disappointment," said Founder and CEO of Ispace Takeshi Hakamada. "We deeply regret that we were unable to meet the expectations of our shareholders, payload customers, HAKUTO-R partners, government officials, and all others who supported us."
"Ispace will not let this be a setback. We will not stop here, but as determined pioneers of the cislunar economy, we will strive to regain the trust of all stakeholders and embark on the next mission.
Chief technology officer at ispace Ryo Ujiie said the company was taking major steps to combat the problem. One is to conduct a better testing plan to see how the laser rangefinder operates under different conditions. The second is to look into getting a different laser rangefinder.
These changes will not be in effect for missions 3 and 4, which are scheduled to launch in 2027.
"We take it very seriously," Takeshi Hakamada, chief executive of ispace, said of the failed landings of its first two missions. "However, the important part is that we keep trying. There can be some failures, but we keep improving our systems."
"Our primary goal today was to convey that ispace, as a challenger, is already moving forward towards its next mission," he said, vowing to regain the trust of its customers and other stakeholders. "We're committed to demonstrating that Ispace will continue to grow undeterred by this setback."
"We take it very seriously," Takeshi Hakamada, chief executive of ispace, said of the failed landings of its first two missions. "However, the important part is that we keep trying. There can be some failures, but we keep improving our systems."
"Our primary goal today was to convey that ispace, as a challenger, is already moving forward towards its next mission," he said, vowing to regain trust of its customers and other stakeholders. "We're committed to demonstrating that ispace will continue to grow undeterred by this setback."
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Entrepreneur
6 minutes ago
- Entrepreneur
Brandworks Technologies Raises USD 7 Million
The funding will be used to expand and upgrade the company's R&D centres, establish partnerships in key international markets, develop next-generation product platforms, and scale manufacturing through new high-efficiency production line You're reading Entrepreneur India, an international franchise of Entrepreneur Media. Brandworks Technologies, an electronics design-led manufacturing company, has raised USD 7 million (approximately INR 61 crore) in a Series A round led by Cactus Partners (CPL), with participation from Gujarat Venture Finance Limited (GVFL), Legacy Assets, and the Hira Group. The funding will be used to expand and upgrade the company's R&D centres, establish partnerships in key international markets, develop next-generation product platforms, and scale manufacturing through new high-efficiency production lines. The company also plans to strengthen its workforce by hiring additional engineering, design, and operations talent. "This fundraise is fuel for a much larger mission — to make Brandworks a global leader in electronics R&D and manufacturing," said Ishwar Kumhar, Co-founder of Brandworks Technologies. "We're here to prove that world-class innovation can be imagined, designed, and built in India, and delivered to the world." Co-founder Nikita Kumawat added, "We are truly delighted to partner with Cactus Partners. Their proactive support and thoughtful involvement have been instrumental for us. As a founder-focused fund with deep expertise in the sector, they bring invaluable insight and commitment to helping ventures like ours succeed." Amit Sharma, General Partner at Cactus Partners, said, "The way Ishwar and Nikita have built this business so far is truly commendable. The robust and consistent growth, while maintaining healthy economics, is a testament to their impeccable execution. Electronics manufacturing as an industry is expected to grow at a healthy pace in the foreseeable future, thanks to the 'Make in India' initiatives and changing supply chains and geopolitics. High-quality and well-managed companies such as Brandworks are well positioned to grow at a significantly faster pace than the industry." Brandworks works across AI hardware, IoT solutions, audio systems, charging technologies, financial devices, surveillance systems, and renewable energy products. It partners with global chip companies to co-create products with a focus on design excellence and manufacturing precision. This is CPL's eleventh investment from its maiden fund and third in the manufacturing sector. Previous investments include Lohum, Indigrid, Intangles, Kapture, Vitraya, AMPM, Auric, Parkmate, Ananant Systems, and Rubix (exited).
Yahoo
3 hours ago
- Yahoo
TELA Bio Inc (TELA) Q2 2025 Earnings Call Highlights: Record Revenue and Strategic Growth ...
Revenue: Increased 26% year over year to $20.2 million. OviTex Revenue Growth: Grew 12% year over year. OviTex PRS Revenue Growth: Increased 53% year over year. OviTex Unit Sales Growth: Grew 17% for the quarter. PRS Unit Sales Growth: Increased 40% for the quarter. Gross Margin: 69.8% for the second quarter, up from 68.8% in the prior year period. Sales and Marketing Expense: $16.9 million, up from $16.7 million in the prior year period. General and Administrative Expense: $4.1 million, up from $3.6 million in the prior year period. R&D Expense: $2.2 million, compared to $2.3 million in the prior year period. Net Loss: $9.9 million, compared to $12.6 million in the prior year period. Cash and Cash Equivalents: $35 million at the end of the second quarter. Full Year 2025 Revenue Guidance: Anticipated to be in the range of $85 million to $88 million, representing growth of 23% to 27% over 2024. Warning! GuruFocus has detected 4 Warning Signs with TELA. Release Date: August 11, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points TELA Bio Inc (NASDAQ:TELA) achieved a record revenue of over $20 million in Q2 2025, marking the first quarter to surpass this milestone. The OviTex reinforced tissue matrix portfolio for hernia repair and abdominal wall reconstruction has scaled significantly, with over 73,000 units sold across the US and Europe. The company secured contracts with three major national GPOs for LIQUIFIX, with two contracts recognizing it as an innovative technology. European sales grew 25% year-over-year, driven by 29% unit growth, and TELA Bio Inc (NASDAQ:TELA) secured a four-year framework agreement with the NHS in England. The company reported a gross margin increase to 69.8% in Q2 2025, up from 68.8% in the prior year period, due to lower charges for excess and obsolete inventory. Negative Points TELA Bio Inc (NASDAQ:TELA) reported a net loss of $9.9 million in Q2 2025, although this was an improvement from a $12.6 million loss in the prior year period. Sales and marketing expenses increased slightly to $16.9 million, primarily due to higher commission expenses, despite a decrease in headcount. General and administrative expenses rose to $4.1 million from $3.6 million in the prior year period. The company is in a transition phase from focusing on complex hernia procedures to a broader portfolio, which may impact short-term growth. Despite strong growth in the OviTex PRS portfolio, the OviTex unit volume growth decelerated, indicating potential challenges in maintaining momentum. Q & A Highlights Q: Can you provide an update on the sales force headcount and any changes expected by the end of 2025? A: Antony Koblish, President and CEO, stated that there are currently 69 territory managers and 25 account specialists, which has been a steady number. The plan is to reach 76 territory managers. Jeffrey Blizard, President, added that they are actively recruiting, with four new candidates in final interviews. Q: Could you elaborate on the changes to spending and focus on a patient-centric culture? A: Jeffrey Blizard, President, mentioned revising the T&E policy to align with Abiomed guidelines and controlling trunk stock and consignment to reduce waste. The focus is on recruiting the right hires who can hold their own in the operating room and emphasize patient outcomes. Q: How are the reinforced tissue matrix contracts impacting growth and adoption? A: Antony Koblish, President and CEO, explained that they have about 25 contracts in place, primarily with larger IDN systems. The reinforced tissue matrix category allows TELA to stand alone outside of tiered pricing and bundling structures, focusing on a patient-centric approach to transcend bundling strategies. Q: What changes are being made to the selling strategy to mitigate risks of commercial disruption? A: Jeffrey Blizard, President, noted that the focus is on shifting to a patient-centric mentality rather than making significant changes. The team already possesses the right skill sets, and the emphasis is on reminding them of the importance of patient outcomes. Q: Can you provide more details on the growth drivers for OviTex PRS and the impact of new configurations? A: Antony Koblish, President and CEO, highlighted the launch of large long-term resorbable PRS products, which are the largest tissue matrices available for PRS. This, along with new clinical data, has driven growth and increased ASP. More PRS products are expected in the future to broaden the portfolio. Q: What gives you confidence in the guidance and expected acceleration in Q4? A: Antony Koblish, President and CEO, explained that the fourth quarter naturally sees higher sales due to factors like health savings account usage and scheduling around holidays. With high productivity from the sales reps and new hires ramping up, they feel confident in meeting guidance. Q: Can you discuss the focus on teaching hospitals and the potential runway in this area? A: Jeffrey Blizard, President, mentioned consulting with MedScout to identify key programs and teaching hospitals. They are refining a strategy to target these institutions, which are numerous across the US and internationally. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
UPI
3 hours ago
- UPI
South Korea's Lee, Trump to hold summit at White House on Aug. 25
1 of 2 | South Korean President Lee Jae Myung will travel to Washington this month for a summit with U.S. President Donald Trump on Aug. 5, Lee's office said Tuesday. File Photo by Thomas Maresca/UPI | License Photo SEOUL, Aug. 12 (UPI) -- South Korean President Lee Jae Myung will travel to Washington to hold a summit with U.S. President Donald Trump on Aug. 25, Lee's office said Tuesday, with trade and defense issues expected to be at the top of the agenda. The three-day visit will be Lee's first trip to the United States since taking office in June, presidential spokeswoman Kang Yu-jung said at a press briefing. "The two leaders plan to discuss ways to develop the Korea-U.S. alliance into a future comprehensive strategic alliance in response to the changing international security and economic environment," Kang said. "They will also discuss ways to further strengthen the robust South Korea-U.S. combined defense posture and to cooperate to establish peace and achieve denuclearization on the Korean Peninsula," she added. The summit comes weeks after Seoul and Washington struck a trade deal that lowered Trump's threatened 25% tariffs on South Korean goods to 15%. As part of the package, South Korea pledged to invest $350 billion in the United States and to purchase $100 billion in U.S. energy. Based on the tariff deal, Trump and Lee will consult on economic cooperation in semiconductors, batteries and shipbuilding, as well as partnerships in advanced technologies and key minerals, Kang said. The future of the decades-old South Korea-U.S. military alliance is also expected to be in the spotlight as the two countries prepare to kick off their annual Ulchi Freedom Shield joint exercise on Monday. During his previous term in office, Trump called for massive increases in Seoul's financial contribution for the 28,500 U.S. forces stationed in Korea. Seoul signed a new five-year cost-sharing agreement with Washington in October, but Trump has suggested he would look to renegotiate the terms of the deal amid calls for allies to increase their defense spending. "South Korea is making a lot of money, and they're very good," Trump told reporters at a Cabinet meeting in the White House last month. "They're very good, but, you know, they should be paying for their own military." On Friday, Gen. Xavier Brunson, commander of U.S. Forces Korea, discussed the need to restructure the military alliance in response to an evolving regional security environment. "Alliance modernization ... reflects the recognition that the world's changed around us," Brunson told local reporters at a press briefing in Pyeongtaek. "We have a nuclear-armed adversary who's north of the border. We have increasing involvement of Russia, along with the DPRK, and we also have the Chinese and the threat that they pose to a free and open Indo-Pacific." The Democratic People's Republic of Korea is the official name of North Korea. Brunson avoided the question of a potential of U.S. troop reduction on the peninsula, stressing military capabilities and strategic flexibility over numbers ahead of the Lee-Trump summit. "We're going to have two chief executives sitting down together to discuss not only the security situation in the region, but the security situation in the world," he said. "For us, it's about the capabilities. We want to have the right capabilities resident on the Peninsula." Lee will be in the United States from Aug. 24-26 for his summit with Trump. In response to local media reports that Lee may also stop in Japan around the time of his U.S. trip, presidential spokeswoman Kang said that nothing had been confirmed.
